LMP 160

Drug Profile

LMP 160

Alternative Names: LMP-160

Latest Information Update: 28 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer LeukoMed
  • Class Antiasthmatics; Antipsoriatics; Indoles
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Psoriasis

Most Recent Events

  • 28 Mar 2011 Discontinued - Preclinical for Asthma in USA (Inhalation)
  • 28 Mar 2011 Discontinued - Preclinical for Psoriasis in USA (Topical)
  • 17 May 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top